Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 3 of 5

“Conventional wisdom has been that patients with more mild herpes have an effective T cell immune response,” says Seth Hetherington, chief medical officer at biotechnology company Genocea, based in Cambridge, Massachusetts

Seth Hetherington, Genocea’s chief medical officer, is helping to develop a therapeutic herpes vaccine that he says is “unique” in its ability to stimulate two arms of the immune system

Source  Courtesy of Seth Hetherington